Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method of testing for pulmonary hypertension

Inactive Publication Date: 2017-03-30
TOHOKU UNIV
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present patent provides a way to easily and accurately test for pulmonary hypertension by analyzing patients' blood. This testing method is done on an outpatient basis, which reduces the burden on both patients and health care providers. As a result, patients with pulmonary hypertension can be proactively tested and receive effective therapy early.

Problems solved by technology

Early diagnosis is difficult, even for cardiologists.
Although there are still no means other than lung transplantation for saving critically ill patients, the number of donors is limited, and there are many cases in which patients die while awaiting transplantation.
The disease advances quickly in many younger-age cases, and death due to right heart failure frequently occurs, even when multidrug therapy is used.
However, the causes of this disease have yet to be fully clarified.
However, subjective symptoms in the early stage of pulmonary hypertension patients are limited to nonspecific symptoms, such as shortness of breath during exertion, and fatigue.
Specifically, hospitalization is necessary to perform pulmonary hypertension tests, thus imposing a great burden on both patients and health care providers.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method of testing for pulmonary hypertension
  • Method of testing for pulmonary hypertension
  • Method of testing for pulmonary hypertension

Examples

Experimental program
Comparison scheme
Effect test

example 1

Test for Pulmonary Hypertension

[0090]The plasma concentration of selenoprotein P protein in pulmonary hypertension patients and non-pulmonary hypertension patients was measured. The pulmonary hypertension patients as subjects were patients diagnosed as having pulmonary arterial hypertension.

Patient Group

[0091]The blood sampled from the following patient groups was subjected to testing.[0092](i) Non-pulmonary hypertension patient (non-PH) group (control group): 19 persons (a group of healthy subjects who were suspected of having a heart disease and underwent a thorough examination, including cardiac catheterization, and in whom no lesion was observed); and[0093](ii) a group of pulmonary hypertension (PH) patients: 146 persons.

[0094]This research was approved beforehand by the Medical Ethics Committee of Tohoku University, and performed with the informed consent and approval of every patient.

Method

[0095]Plasma was separated from peripheral vein-derived blood samples and pulmonary arte...

example 2

Pulmonary Hypertension Test

[0097]The plasma concentration of selenoprotein P protein was measured in pulmonary hypertension patients and in non-pulmonary hypertension patients in the same manner as in Example 1.

Patient Group

[0098]The blood sampled from the following patient groups was tested.[0099](i) Non-pulmonary hypertension patient (non-PH) group (control group): 20 persons; and[0100](ii) pulmonary hypertension patient (PH) group: 183 persons.

[0101]The detailed breakdown of the pulmonary hypertension patients is as follows:[0102]connective tissue disease [CPAH; Group 1, 4)−1, Nice Classification]: 25 persons;[0103]chronic thromboembolic pulmonary hypertension [CTEPH; Group 4, Nice Classification]: 51 persons;[0104]idiopathic pulmonary arterial hypertension [IPAH; Group 1, 1, Nice Classification]: 58 persons;[0105]pulmonary hypertension associated with lung diseases and / or hypoxemia [Lung-PAH; Group 3, Nice Classification]: 10 persons;[0106]pulmonary hypertension associated with ...

reference example 1

[0112]The response of pulmonary artery smooth muscle cells (PASMC) in idiopathic pulmonary arterial hypertension (IPAH) patients (hereinafter also referred to as IPAH-PASMC) to hypoxia stimulation was observed.

Material

[0113]Primary cell lines were established from pulmonary vascular smooth muscle in idiopathic pulmonary arterial hypertension patients, in accordance with the following document: Ogawa A, Nakamura K, Matsubara H, Fujio H, Ikeda T, Kobayashi K, Miyazaki I, Asanuma M, Miyaji K, Miura D, Kusano K F, Date H, Ohe T, Circulation, 2005; 112: 1806-1812. The pulmonary vascular smooth muscle in idiopathic pulmonary arterial hypertension patients was isolated from pulmonary arteries having an outer diameter of 1.5 mm or less.

Culture Conditions

[0114]IPAH-PASMC was cultured in D-MEM medium supplemented by 10% FBS (fetal bovine serum) at 37° C. under constant temperature and constant humidity conditions at 95% air and 5% CO2 in accordance with a usual method. In this test, passage 4...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A primary object of the present invention is to provide a method for conveniently and accurately testing for pulmonary hypertension. To achieve this object, the present invention provides a method for testing for pulmonary hypertension using as an indicator the concentration of selenoprotein P protein in a sample derived from a subject.

Description

TECHNICAL FIELD[0001]The present invention mainly relates to a method of testing for pulmonary hypertension. The present invention further relates to a biomarker for detecting pulmonary hypertension, and a test kit for pulmonary hypertension.BACKGROUND ART[0002]Pulmonary hypertension is a disease in which pulmonary artery blood pressure is increased due to a variety of causes. According to WHO classification or the like, pulmonary hypertension is classified into pulmonary arterial hypertension (PAH), pulmonary hypertension due to left heart disease, pulmonary hypertension due to lung disease and / or hypoxia, chronic thromboembolic pulmonary hypertension (CTEPH)), and pulmonary hypertension of unknown cause due to a combination of factors (Non-patent Literature (NPL) 1 to 5). In Japan, pulmonary hypertension includes many diseases designated as intractable diseases (specified diseases). In the case of patients at the terminal stage, lung transplantation may be necessary.[0003]For exam...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N33/68
CPCG01N33/6893G01N2333/47G01N2800/12G01N33/68
Inventor SHIMOKAWA, HIROAKISATOH, KIMIOKIKUCHI, NOBUHIRO
Owner TOHOKU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com